Background and purpose: We prospectively examine the single and combined predictive value of biological and clinical markers in recurrent strokes related to intracranial atherosclerotic disease (ICAD). Methods: In 73 ICAD first-ever stroke patients, ankle-brachial index (ABI) was assessed three months after TIA or stroke together with CRP, Lp-PLA2, ICAM-1, E-selectin and PAI-1 measurements. Appearance of new TIA/stroke was assessed every 6 months. Results: After a median follow-up of 22.4 months, 13 patients (17.8%) suffered a new stroke or TIA. Risk of new cerebrovascular events (CVEs) was associated with lowered ABI (p=0.011), baseline PAI-1. 22.52. ng/ml (<0.001), E-selectin. 24.75. ng/ml (p=0.008) and ICAM-1. 205. ng/ml (p=0.029). The combination of PAI-1 with ABI or ESRS reclassified 55.4% (p<. 0.005) and 48.3% (p<. 0.05) of patients between low, high and very high-risk categories. Conclusions: This tentative study shows that ABI and PAI-1 are associated with the risk of new CVEs in symptomatic ICAD patients, and their combination might improve identification of patients at higher risk. © 2014 Elsevier Ireland Ltd.
|Publication status||Published - 1 Mar 2014|
- Ankle-brachial index
- Intracranial atherosclerotic disease
- Intracranial stenosis